Abstract
The new generation fluoroquinolones — sparfloxacin, levofloxacin, grepafloxacin and trovafloxacin — have been designed to respond to the clinical need for extended antimicrobial cover in the face of increasing global microbial resistance. Their main focus is in the treatment of respiratory infections, particularly those acquired in the community.
CNS adverse effects, such as dizziness and headache, are known to occur relatively commonly with some fluoroquinolones and are not, in general, well tolerated by patients. The structural component of the fluoroquinolone molecule believed to be responsible for improved Gram-positive activity is also believed to be implicated in the production of CNS adverse effects, including those arising from drug interactions with theophylline and NSAIDs.
Inhibition of brain γ-aminobutyric acid (GABA) receptor binding appears to be a strong indicator of CNS activity, though N-methyl-D-aspartate receptor binding has also been implicated. In accordance with the results of these predictive studies, clinical trials have found sparfloxacin, levofloxacin and grepafloxacin to be associated with a low incidence of CNS events. Trovafloxacin has been found to be associated with a higher incidence of CNS events (particularly lightheadedness and dizziness) than the other 3 agents. Ongoing and future clinical studies will help to define the usefulness of the predictive models, as well as reveal the full CNS adverse event profile of these and other investigational fluoroquinolones.
Similar content being viewed by others
References
The European Agency for the Evaluation of Medicinal Products. Public statement on Trovan/Trovan IV/Turvel/Turvel IV (Trovafloxacin/Alatrofloxacin). Recommendation to suspend the marketing authorisation in the European Union. London: Human Medicines Evaluation Unit, 15 Jun 1999
Paton DH, Reeves DS. Adverse reactions to the fluoro-quinolones. Adv Drug React Bull 1992; 153: 575–8
Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Drug Saf 1995; 13: 343–58
Halliwell RF, Davey PG, Lambert JJ. Antagonism of GABA receptors by 4-quinolones. J Antimicrob Chemother 1993; 31: 457–62
Green MA, Halliwell RF. Selective antagonism of the GABAA receptor by ciprofloxacin and biphenylacetic acid. Br J Pharmacol 1997; 122: 584–90
Davey PG. Overview of drug interactions with the quinolones. J Antimicrob Chemother 1988; 22 Suppl. C: 97–107
Ito T, Miura Y, Kadokawa T, et al. Effects of enoxacin and its combination with 4-biphenylacetate, an active metabolite of fenbufen, on population spikes in rat hippocampal slices. Pharmacol Toxicol 1991; 68: 220–5
Hori S, Shimada J. Effect of grepafloxacin, a new fluoroquinolone on gamma-aminobutyric acid binding: a comparative study of epileptogenic activity of quinolones. Jpn J Chemother 1995; 43 Suppl. 5: 150–4
Wijnands WJA, Vree TB, van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986; 22: 677–83
Karki SD. Bentley DW. Raghavan M. Seizure with ciprofloxacin and theophylline combined therapy. DICP 1990; 24(6): 595–6
Geddes AM. Grepafloxacin — focus on respiratory tract infections. J Antimicrob Chemother 1997; 40 Suppl. A: 1–4
Cooper B, Lawler M. Pneumococcal bacteraemia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med 1989; 87: 475
Righter J. Pneumococcal meningitis during intravenous ciprofloxacin therapy [letter]. Am J Med 1990; 88(5): 548
Gordon J, Kauffman CA. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med 1990; 89(3): 383–4
Perez-Trallero E, Garcia-Arenzana M, Jiminez A, et al. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Infect Dis 1990; 9: 905–6
Branthwaite A, Péchère J.-C. Pan-European survey of patients’ attitudes to antibiotics and antibiotic use. J Int Med Res 1996; 24: 220–38
Gonzalez JP, Henwood IM. Pefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1989; 37: 628–68
Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677–706
Yamauchi D, Goto T, Makinose S, et al. Clinical effect of grepafloxacin in the treatment of genitourinary infections and its penetration into human cerebrospinal fluid. Jpn J Chemother 1995; 43 Suppl. 1: 405–9
Goto T, Eta S, Kitagawa T, et al. In vitro activity, penetration to cerebrospinal fluid and clinical evaluation of balofloxacin in urinary tract infections. Jpn J Chemother 1995; 43 Suppl. 5: 330–5
Cutler NR, Vincent J, Jhee SS, et al. Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin. Antimicrob Agents Chemother 1997; 41: 1298–300
Ostergaard C, Sorensen TK, Knudsen JD, et al. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother 1998; 42: 1706–12
Davey PG, Charter M, Kelly S, et al. Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. Antimicrob Agents Chemother 1994; 38: 1356–62
Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994; 33: 685–706
Akahane K, Sekiguchi M, Une T, et al. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 1989; 33: 1704–8
Tsutomi Y, Matsubayashi K, Akahane K. Quantitation of GABAA receptor inhibition required for quinolone-induced convulsions in mice. J Antimicrob Chemother 1994; 34: 737–46
Ito Y, Miyasaka T, Fukuda H, et al. Inhibition of GABAAreceptor chloride channel by quinolones and norfloxacin-biphenylacetic acid hybrid compounds. Neuropharmacology 1996; 35: 1263–9
Kohno K, Niwa M, Nozaki M, et al. Role of nitric oxide in the convulsive seizures induced by fluoroquinolones coadministered with 4-biphenylacetic acid. Gen Pharmacol 1997; 29: 767–70
Masukawa T, Nakanishi K, Natsuki R. Role of nitric oxide in the convulsions following the coadministration of enoxacin with fenbufen in mice. Jpn J Pharmacol 1998; 76: 425–9
Shintani S, Kusunoki A, Hosoki E. Drug interaction of OPC-17116, a new quinolone antibacterial agent, with non-steroidal anti-inflammatory drugs in experimental animals [abstract no. 1479]. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy 1991; 1991 Sept 29–Oct 2; Chicago (IL): 345
Hori S, Shimada J. Effect of balofloxacin, a newly synthesized quinolone, on GABA receptor binding and its convulsant activity in mice. Jpn J Chemother 1995; 43 Suppl. 5: 111–4
Akahane K, Tsutomi Y, Kimura Y, et al. Levofloxacin, an optical isomer of ofloxacin, has attenuated epileptogenic activity in mice and inhibitory potency in GABAreceptor binding. Chemotherapy 1994; 40: 412–7
Lambert J, Page A, Callachan H, et al. The interaction of quinolone antibiotics with the rat GABAA receptor complex. 21st International Congress of Chemotherapy [abstract no.253]; 1999 Jul 4–7; Birmingham
Schmuck G, Schürmann, Schlüter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998; 42: 1831–6
Ellinwood EH, Lee TH. Central nervous system stimulants and anorectic agents. In: Dukes MNG, editor. Meyers side effects of drugs. 13th ed. Amsterdam, Lausanne, New York, Oxford, Shannon, Tokyo: Elsevier: 1-30
Mizuki Y, Fujiwara I, Yamaguchi T, et al. Structure-related inhibitory effect of antimicrobial enoxacin and derivatives on theophylline metabolism by rat liver microsomes. Antimicrob Agents Chemother 1996; 40: 1875–80
Gisclon LG, Curtin CR, Fowler CL, et al. Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin. J Clin Pharmacol 1997; 37: 744–50
Goa KL, Bryson HM, Markham A. Sparfloxacin: a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997; 53: 700–25
Vincent J, Venitz J, Teng R, et al. Effect of trovafloxacin, a new fluoroquinolone antibiotic, on the steady state pharmacokinetics of theophylline in healthy volunteers. J Antimicrob Chemother 1997; 39 Suppl. B: 81–6
Niki Y, Itokawa K, Okazaki O. Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Antimicrob Agents Chemother 1998; 42: 1751–5
Efthymiopoulos C, Bramer SL, Maroli A, et al. Theophylline and warfarin interaction studies with grepafloxacin. Clin Pharmacokinet 1997; 33 Suppl. 1: 39–46
Matuschka PR, Vissing RS. Clinafloxacin-theophylline drug interaction. Ann Pharmacother 1995; 29: 378–80
Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomised comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995; 8: 1999–2007
Portier H, May T, Proust A. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia: French Study Group. J Antimicrob Chemother 1996; 37 Suppl. A: 83–91
Bensch G, for the SPAR multicenter CAP study group. Treatment of community-acquired pneumonia (CAP) with sparfloxacin and cefaclor [abstract LM-12]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996; 15–18 Sep 1996; New Orleans (LA): 282
Ortqvist A, Valtonen M, Cars O, et al. Oral empiric treatment of community-acquired pneumonia: a multicenter, doubleblind, randomized study comparing sparfloxacin with roxithromycin: the Scandinavian Sparfloxacin Study Group. Chest 1996; 110: 1499–506
Donowitz GR, Brandon ML, Salisbury JP, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study. Clin Ther 1997; 19: 936–53
Aubier M, Verster R, Regamey C, et al. Once-daily sparfloxacin versus high-dosage amoxycillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults: Sparfloxacin European Study Group. Clin Infect Dis 1998; 26: 1312–20
Allegra L, Konietzko N, Leophonte P, et al. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel multicentre study. J Antimicrob Chemother 1996; 37 Suppl. A: 93–104
DeAbate CA, Henry D, Bensch G, et al. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study: Sparfloxacin Multicenter ABECB Study Group. Chest 1998; 114: 120–30
Gehanno P, Berche P. Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis: Sinusitis Study Group. J Antimicrob Chemother 1996; 37 Suppl. A: 105–14
Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996; 37 Suppl. A: 145–60
Fogarty CM. A noncomparative study to evaluate the safety and efficacy of levofloxacin in the treatment of community-acquired pneumonia in adults [poster]. 19th International Conference of Chemotherapy 1995; Montreal
Adeglass J, Deabate AC, Mcelvaine P. A comparison of levofloxacin q.d. and amoxicillin-clavulanate t.i.d. for the treatment of acute bacterial sinusitis [abstract no. 290]. 34th Infectious Diseases Society of America 1996; 1996 Sep 18–20; New Orleans (LA): 280
Habib MP, Gentry LO, Rodriguez-Gomez G. A multicenter randomised study comparing the efficacy and safety of oral levofloxacin vs cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis [abstract no. LM2]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans (LA): 371
Carbon C and members of The International Study Group. Comparative study of levofloxacin and co-amoxiclav in the treatment of community-acquired pneumonia in adults [abstract no. LM-70]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 377
Deabate CA, Russell M, Mcelvaine P. Safety and efficacy of oral levofloxacin vs cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997; 42: 206–13
File TM, Segreti J, Dunbar L. A multicenter, randomized, study comparing the efficacy and safety of intravenous and/or oral levofloxacin versusceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965–72
Shah PM and the International Study Group. Levofloxacin vs cefuroxime axetil in the treatment of acute exacerbations of chronic bronchitis [abstract no. LM-38]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997; Toronto, 1997 Sep 28–Oct 1; 371
Sydnor TA, Scheld WM, Gwaltney JM. An open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults. Ann Allergy Asthma Immunol 1998; 80: 357–62
Richards GA, Klimberg IN, Fowler CL, et al. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998; 52: 51–5
Nichols R, Smith J, Gentry LO, et al. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J 1997; 90: 1193–200
Nicodemo AC, Robledo JA, Jasovich A, et al. A multicenter, double-blind, randomized study comparing the efficacy and safety of oral levofloxacin versusciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract 1998; 52: 69–74
Andrews JM, Honeybourne D, Jevons G, et al. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 40: 573–7
Langan CE, Cranfield R, Breisch S, et al. Randomised, double-blind study of grepafloxacin versusamoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 Suppl. A: 63–72
Chodosh S, Lakshminarayan S, Swarz H, et al. The efficacy and safety of a 10-day course of grepafloxacin 400 mg once daily in the treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of ciprofloxacin 500 mg twice daily. Antimicrob Agents Chemother 1998; 42: 114–20
O’Doherty B, Dutchman DA, Petit R, et al. Randomised, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997; 40 Suppl. A: 73–82
Topkis S, Swarz H, Breisch S, et al. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia. Curr Ther Res 1997; 19: 975–88
Adams M, Sullivan J, Henry D, et al. Comparison of grepafloxacin with cefaclor in the treatment of community-acquired pneumonia [abstract no. LM-68]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997; 1997 Sep 28–Oct 1; Toronto, 377
Patel T, Desai R, Duff, J et al. Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia [abstract no. LM-69]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997; 1997 Sep 28–Oct 1; Toronto, 377
Hook EW, McCormack WM, Martin D, et al. Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhoea in men. Antimicrob Agents Chemother 1997; 41: 1843–5
Mroczkowski TF, Hook EW, Jones RB, et al. The efficacy and safety of single-dose grepafloxacin 400 mg in the treatment of uncomplicated gonococcal cervicitis in females: comparison with cefixime 400 mg [abstract no. P411]. 8th European Congress of Clinical Microbiology and Infectious Diseases; 1997 May 28; Lausanne: 25–93
McCormack WM, Martin DH, Hook III EW, et al. Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection. Infect Dis Obstet Gynecol 1998; 6(3): 109–15
Data on file, Glaxo Wellcome, 1996
Lode H, Vogel F, Elies W. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance. Clin Ther 1999; 21(1): 61–74
Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219) a new quinolone antibiotic following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother 1995; 36: 385–94
Teng R, Liston TE, Harris SC. Multiple dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996; 37; 955–63
Williams D, Hopkins S. Safety of trovafloxacin in treatment of lower respiratory tract infections. Eur J Clin Micro Infect Dis 1998; 17: 454–8
Sullivan J, Gezon J, Williams Hopkins D, et al. A double-blind, randomized multicenter study in ambulatory community-acquired pneumonia comparing trovafloxacin with clarithromycin [abstract no. LM-73]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 27–Oct 1; Toronto, 378
Niederman M, Traub S, Ellison WT, et al. A double-blind, randomized multicenter, global study in hospitalized community-acquired pneumonia comparing trovafloxacin with ceftriaxone + erythromycin [abstract no. LM-72]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 377
Graham DR, Klein T, Torres A, et al. A double-blind randomised multicenter study of nosocomial pneumonia comparing trovafloxacin with ciprofloxacin ± clindamycin/metronidazole [abstract no. LM-74]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 378
Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995; 39: 170–4
Bron NJ, Dorr MB, Mant TG, et al. The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects. J Antimicrob Chemother 1996; 38: 1023–9
Sprikslee M, Reiter C, Meyer JM. Safety and tolerability profile of moxifloxacin [abstract no. P208]. 9th European Congress of Clinical Microbiology and Infectious Diseases; 1999 Mar 21–24; Berlin, 140
Martin SJ, Meyer JM, Chuck SK, et al. Levofloxacin and sparfloxacin: new quinolone antibiotics. Ann Pharmacother 1998; 32: 320–36
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lode, H. Potential Interactions of the Extended-Spectrum Fluoroquinolones with the CNS. Drug-Safety 21, 123–135 (1999). https://doi.org/10.2165/00002018-199921020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199921020-00005